

NDA 21-265/S-001

Page 3

For dilution in intravenous infusions only

INFUVITE *Pediatric*
Multiple Vitamins for Infusion

INFUVITE *Pediatric*

Multiple Vitamins for Infusion

DESCRIPTION

INFUVITE *Pediatric* is a sterile product consisting of two vials: a 4 mL single-dose vial labeled Vial 1 and a 1 mL single-dose vial labeled Vial 2.

Each 4 mL of Vial 1 provides:

Ascorbic acid (Vitamin C).....	80 mg
Vitamin A* (as palmitate).....	2 300 IU
Vitamin D ₃ * (cholecalciferol).....	400 IU
Thiamine (Vitamin B ₁) (as the hydrochloride).....	1.2 mg
Riboflavin (Vitamin B ₂) (as riboflavin 5-phosphate sodium).....	1.4 mg
Pyridoxine HCl (Vitamin B ₆).....	1 mg
Niacinamide.....	17 mg
Dexpanthenol (as <i>d</i> -pantothenyl alcohol).....	5 mg
Vitamin E* (<i>dl</i> - α -tocopheryl acetate).....	7 IU
Vitamin K ₁ *.....	0.2 mg

Inactive ingredients: 50 mg polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment and water for injection.

** Polysorbate 80 is used to water solubilize the oil-soluble vitamins A, D, E and K.

Each 1 mL of Vial 2 provides:

Folic acid.....	140 mcg
Biotin.....	20 mcg
Vitamin B ₁₂ (cyanocobalamin).....	1 mcg

Inactive ingredients: 75 mg mannitol, citric acid and/or sodium citrate for pH adjustment and water for injection.

NDA 21-265/S-001

Page 4

Vitamin A 2,3000 IU equals 0.7 mg

Vitamin D 400 IU equals 10 mcg

Vitamin E 7 IU equals 7 mg

Multiple vitamin preparation for intravenous infusion:

INFUVITE *Pediatric* (Multiple Vitamins for Infusion) makes available a combination of important oil-soluble and water-soluble vitamins in an aqueous solution, formulated for incorporation into intravenous solutions. The liposoluble vitamins A, D, E and K have been solubilized in an aqueous medium with polysorbate 80, permitting intravenous administration of these vitamins.

INDICATIONS AND USAGE

INFUVITE *Pediatric* is indicated as a daily multivitamin maintenance dosage for infants and children up to 11 years of age receiving parenteral nutrition.

INFUVITE *Pediatric* is also indicated in other situations where administration by the intravenous route is required. Such situations include surgery, extensive burns, fractures and other trauma, severe infectious diseases, and comatose states, which may provoke a "stress" situation with profound alterations in the body's metabolic demands and consequent tissue depletion of nutrients.

The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy.

INFUVITE *Pediatric* (administered in intravenous fluids under proper dilution) contributes intake of necessary vitamins toward maintaining the body's normal resistance and repair processes.

Patients with multiple vitamin deficiencies or with markedly increased requirements may be given multiples of the daily dosage for two or more days, as indicated by the clinical status. Blood vitamin concentrations should be periodically monitored to ensure maintenance of adequate levels, particularly in patients receiving parenteral multivitamins as their sole source of vitamins for long periods of time.

CONTRAINDICATIONS

INFUVITE *Pediatric* is contraindicated where there is a pre-existing hypervitaminosis, or a known hypersensitivity to any of the vitamins or excipients in the product.

Allergic reaction has been known to occur following intravenous administration of thiamine and vitamin K. The formulation is contraindicated prior to blood sampling for detection of megaloblastic anemia, as the folic acid and the cyanocobalamin in the vitamin solution can mask serum deficits.

WARNINGS

INFUVITE *Pediatric* is administered in intravenous solutions, which may contain aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solution, which contain aluminum.

NDA 21-265/S-001

Page 5

Research indicates that patients with impaired kidney function, including premature neonates who receive parenteral levels of aluminum at greater than 4 to 5 µg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

PRECAUTIONS

Caution should be exercised when administering INFUVITE *Pediatric* to patients on warfarin sodium-type anticoagulant therapy. In such patients, vitamin K may antagonize the hypoprothrombinemic response to anticoagulant drugs. In such patients, periodic monitoring of prothrombin time/INR response is essential in determining the appropriate dosage of anticoagulant therapy.

Adequate blood levels of vitamin E are achieved when **INFUVITE *Pediatric*** is given to infants at the recommended dosage. Larger doses or supplementation with oral or parenteral vitamin E are not recommended because elevated blood levels of vitamin E may result.

Studies have shown that vitamin A may adhere to plastic, resulting in inadequate vitamin A administration in the doses recommended with **INFUVITE *Pediatric***. Additional vitamin A supplementation may be required, especially in low birth weight infants.

Long standing specific vitamin deficiencies may require additional therapeutic amounts of specific vitamins to supplement the maintenance vitamins provided by **INFUVITE *Pediatric***.

In patients receiving parenteral multivitamins, blood vitamin concentrations should be periodically monitored to determine if vitamin deficiencies or excesses are developing.

Polysorbates have been associated with the E-Ferol syndrome (thrombocytopenia, renal dysfunction, hepatomagaly, cholestasis, ascites, hypotension and metabolic acidosis) in low birth weight infants. However, no such adverse reports have been associated with the use of pediatric multiple vitamins for infusion such as **INFUVITE *Pediatric***.

INFUVITE *Pediatric* should be aseptically transferred to the infusion fluid.

DRUG-DRUG INTERACTIONS

Physical incompatibilities: **INFUVITE *Pediatric*** (Multiple Vitamins for Infusion) is not physically compatible with alkaline solutions or moderately alkaline drugs such as acetazolamide, and chlorothiazide sodium, aminopylline or sodium bicarbonate. **INFUVITE *Pediatric*** is not physically compatible with ampicillin and it may not be physically compatible with tetracycline HCl. It has also been reported that folic acid is unstable in the presence of calcium salts such as calcium gluconate. Direct addition to intravenous fat emulsions is not recommended. Consult appropriate references for listings of physical compatibility of solutions and drugs with the vitamin infusion. In such circumstances, admixture or Y-site administration with vitamin solutions should be avoided.

NDA 21-265/S-001

Page 6

Some of the vitamins in **INFUVITE *Pediatric*** may react with vitamin K bisulfite or sodium bisulfite; if bisulfite solutions are necessary, patients should be monitored for Vitamin A, thiamine and ascorbic acid deficiencies.

Clinical Interactions: A number of interactions between vitamins and drugs have been reported which may affect the metabolism of either agent. The following are examples of these types of interactions.

Folic acid may lower the serum concentration of phenytoin resulting in increased seizure frequency. Conversely, phenytoin may decrease serum folic acid concentrations and, therefore, should be avoided in pregnancy. Folic acid may decrease the patient's response to methotrexate therapy.

Pyridoxine may decrease the efficacy of levodopa by increasing its metabolism. Concomitant administration of hydralazine or isoniazid may increase pyridoxine requirements.

In patients with pernicious anemia, the hematological response to vitamin B₁₂ therapy may be inhibited by concomitant administration of chloramphenicol.

Several vitamins have been reported to decrease the activity of certain antibiotics. Thiamine, riboflavin, pyridoxine, niacinamide, and ascorbic acid have been reported to decrease the antibiotic activity of erythromycin, kanamycin, streptomycin, doxycycline, and lincomycin. Bleomycin is inactivated *in vitro* by ascorbic acid and riboflavin.

Vitamin K may antagonize the hypoprothrombinemic effect of oral anticoagulants.

Consult appropriate references for additional specific vitamin-drug interactions.

Drug-Laboratory Test Interactions: Ascorbic acid in the urine may cause false negative urine glucose determinations.

Carcinogenesis, Mutagenesis, and Impairment of Fertility: Carcinogenicity, mutagenesis and fertility studies have not been performed.

ADVERSE REACTIONS

There have been rare reports of anaphylactic reactions following parenteral multivitamin administration. Rare reports of anaphylactoid reactions have also been reported after large intravenous doses of thiamine. The risk, however, is negligible if thiamine is co-administered with other vitamins of the B group. There have been no reports of fatal anaphylactoid reactions associated with multivitamin preparations for infusion.

There have been rare reports of the following types of reactions:

Dermatologic - rash, erythema, pruritis

CNS - headache, dizziness, agitation, anxiety

NDA 21-265/S-001

Page 7

Ophthalmic - diplopia

Allergic - urticaria, shortness of breath, wheezing and angioedema.

OVERDOSAGE

The possibility of hypervitaminosis A or D should be borne in mind. Clinical manifestations of hypervitaminosis A have been reported in patients with renal failure receiving 1.5 mg/day retinol. Therefore, vitamin A supplementation of renal failure patients should be undertaken with caution.

DOSAGE AND ADMINISTRATION

INFUVITE *Pediatric* is ready for immediate use in infants and children up to 11 years of age when added to intravenous infusion fluids.

INFUVITE *Pediatric* should not be given as a direct, undiluted intravenous injection as it may give rise to dizziness, faintness and possible tissue irritation.

A daily dose of INFUVITE *Pediatric* (4 mL of Vial 1 plus 1 mL of Vial 2) should be added directly to not less than 100 mL of intravenous dextrose, saline or similar infusion solutions.

For administration to infants weighing < 1 kg: The daily dose is 30% of the contents of Vial 1 (1.2 mL) and of Vial 2 (0.3 mL). Do not exceed this daily dose. Supplemental vitamin A may be required for low-birth-weight infants.

For administration to infants weighing \geq 1 kg and < 3 kg: The daily dose is 65% of the contents of Vial 1 (2.6 mL) and of Vial 2 (0.65 mL). Do not exceed this daily dose. Supplemental vitamin A may be required for low-birth-weight infants.

For administration to infants and children weighing \geq 3 kg up to 11 years of age: The daily dose is the entire contents of Vial 1 (4 mL) and of Vial 2 (1 mL), unless there is clinical or laboratory evidence for increasing or decreasing the dosage.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

After **INFUVITE *Pediatric*** is diluted in an intravenous infusion, the resulting solution is ready for immediate use. Some of the vitamins in this product, particularly A, D and riboflavin, are light sensitive, therefore, exposure to light should be minimized.

DISCARD ANY UNUSED PORTION

Store between 2-8 °C (36-46 °F).

NDA 21-265/S-001
Page 8

HOW SUPPLIED

INFUVITE *Pediatric* - NDC 54643-5646-0, is available in boxes containing 2 vials - Vial 1 (4 mL) and Vial 2 (1 mL), both vials to be used for a single dose.

INFUVITE *Pediatric* - NDC 54643-5646-1, is available in boxes containing 10 vials – 5 each of Vial 1 (4 mL) and 5 each of Vial 2 (1 mL), one Vial 1 plus one Vial 2 to be used for a single dose.

Rx only.

Distributed by: *(To be determined)*

Manufactured by:
Sabex Inc.
145 Jules-Leger Street
Boucherville, QC, Canada J4B 7K8

Issued: Month/Year

**DRAFT OUTER LABEL - INFUVITTE Pediatric (SINGLE DOSE PACKAGE SIZE)
(TOP FLAP)**

**INFUVITTE Pediatric
Multiple Vitamins for Infusion**

For intravenous infusion after dilution only.

(SIDE PANEL)

The contents of both vials should be added to not less than 100 mL infusion fluid.

Usual Dosage: See Package Insert.

Distributed by: *(To be determined)*

Manufactured by:

Sabex Inc.

Boucherville, Qc, Canada J4B 7K8

Lot.
Exp.

(FRONT PANEL)

NDC xxxxx xxx x

Sterile

**INFUVITTE Pediatric
Multiple Vitamins for Infusion**

For intravenous infusion after dilution only.

Contents: Vial 1 (4 mL) and Vial 2 (1 mL).

Both vials to be used for a single dose.

Store under refrigeration, 2-8 °C (36-46 °F)

Rx only.



(BACK PANEL)

**INFUVITTE Pediatric
Multiple Vitamins for Infusion**

Each 4 mL of Vial 1 provides:

Vitamin C	80 mg
Vitamin A	2 300 I.U.
Vitamin D	400 I.U.
Thiamine (B ₁)	1.2 mg
Riboflavin (B ₂)	1.4 mg
Pyridoxine HCl (B ₆)	1 mg
Niacinamide	17 mg
Dexpanthenol	5 mg
Vitamin E (<i>dl</i> - α -tocopheryl acetate)	7 I.U.
Vitamin K ₁	0.2 mg

with 50 mg polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment, and water for injection.

Each 1 mL of Vial 2 provides:

Folic acid	140 mcg
Biotin	20 mcg
Cyanocobalamin (B ₁₂)	1 mcg

with 75 mg mannitol, citric acid and/or sodium citrate for pH adjustment and water for injection.

DRAFT OUTER LABEL - INFUVITTE Pediatric (PACKAGE SIZE FOR 5 SINGLE DOSES)
(TOP FLAP)

INFUVITTE Pediatric
Multiple Vitamins for Infusion

For intravenous infusion after dilution only.

(SIDE PANEL)

The contents of both vials should be added to not less than 100 mL infusion fluid.

(FRONT PANEL)

NDC xxxxx xxxx x

Sterile

INFUVITTE Pediatric
Multiple Vitamins for Infusion

Usual Dosage: See Package Insert

For intravenous infusion after dilution only.

Distributed by: **(To be determined)**

Contains 5 each of Vial 1 (4 mL) and Vial 2 (1 mL).
One vial of each to be used for a single dose.

Manufactured by:

Store under refrigeration, 2-8 °C (36-46 °F)

Sabex Inc.
Boucherville, Qc, Canada J4B 7K8

Rx only.

Lot.
Exp.



(BACK PANEL)

INFUVITTE Pediatric
Multiple Vitamins for Infusion

Each 4 mL of Vial 1 provides:

Vitamin C..... 80 mg
Vitamin A..... 2 300 IU.
Vitamin D..... 400 IU.
Thiamine (B₁)..... 1.2 mg
Riboflavin (B₂)..... 1.4 mg
Pyridoxine HCl (B₆)..... 1 mg
Niacinamide..... 17 mg
Dexpanthenol..... 5 mg
Vitamin E (*dl*- α -tocopheryl acetate)..... 7 I.U.
Vitamin K₁..... 0.2 mg
with 50 mg polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment, and water for injection.

Each 1 mL of Vial 2 provides:

Folic acid..... 140 mcg
Biotin..... 20 mcg
Cyanocobalamin (B₁₂)..... 1 mcg
with 75 mg mannitol, citric acid and/or sodium citrate for pH adjustment and water for injection.

NDA 21-265/S-001
Page 11

DRAFT INNER LABEL - INFUVITTE Pediatric VIAL 1

Dilute Vials 1 and 2 in not less than 100 mL infusion fluid.
NDC xxxxxx xxxx x 4 mL

USUAL DOSAGE: See package insert.

INFUVITTE Pediatric
Multiple Vitamins for Infusion

VIAL 1

Manufactured by:
Sabex Inc.
Boucherville, Qc, Canada J4B 7K8

For intravenous infusion after dilution only.

Single Use Vial – Sterile

Lot.
Exp.
Store under refrigeration, 2-8 °C (36-46 °F)

Rx only.

Each 4 mL of Vial 1 provides:

Vitamin C.....	80 mg
Vitamin A.....	2 300 I.U.
Vitamin D.....	400 I.U.
Thiamine (B ₁).....	1.2 mg
Riboflavin (B ₂).....	1.4 mg
Pyridoxine HCl (B ₆).....	1 mg
Niacinamide.....	17 mg
Dexpanthenol.....	5 mg
Vitamin E (<i>dl</i> - α -tocopheryl acetate).....	7 I.U.
Vitamin K ₁	0.2 mg

with 50 mg polysorbate 80, sodium hydroxide and/or hydrochloric acid for pH adjustment, and water for injection.



NDA 21-265/S-001
Page 12

DRAFT INNER LABEL - INFUVITE *Pediatric* VIAL 2

	NDC xxxxx xxxx x	1 mL
USUAL DOSAGE: See package insert.	INFUVITE <i>Pediatric</i> Multiple Vitamins for Infusion	
	VIAL 2	
Manufactured by: Sabex Inc. (CANADA)	IV infusion after dilution.	
Distributed By: XXXXXXXX	Single Use Vial - Sterile	
Lot.	Store under refrigeration, 2-8 °C (36-46 °F)	
Exp.	Rx only.	
		

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

David Orloff
10/3/01 06:41:46 PM